explore -WSS

explore

author：entertainment 2025-09-30 16:29:02 - browse：2133

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Zepbound, Valneva's vaccine, and more

hotspot

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

Readout LOUD podcast: Merger Mondays, Ozempic panic

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Cancer cells are shown to suck energy source from immune cells

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

DIEP, the 'gold standard' of breast reconstruction, is under threat

Akero's treatment for NASH falls short in cirrhosis study

Affirmative action in medical school literally saved lives

Wellcome Trust names Røttingen as its new CEO

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Continuity nursing helped my family in our darkest PICU moments

European regulators recommend Amylyx's ALS drug be rejected

explore

Nick Jonas talks about managing diabetes along with his career

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

What health policies could hitch a ride on a spending bill?

Akero's treatment for NASH falls short in cirrhosis study

What is STAT's opinion section for?

There’s no way to know how good AI health technologies are

hotspot

entertainment

leisure time

entertainment